ALT stock forecast, quote, news & analysis
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases... Show more
Why Altimmune (ALT) Stock Is Down -31% in the Last 30 Days
Key Takeaways
- Altimmune (ALT) shares declined roughly 31% over the last 30 days, falling from about $2.96 to near $2.04.
- The pullback followed a strong run-up that pushed the stock to a multi-month high around $3.42 in early September.
- Over the last quarter, ALT has also lost approximately 30%, erasing gains tied to positive pemvidutide clinical data reported in July and August.
- No single company-specific negative event drove the slide; the decline reflects profit-taking and thinning near-term catalysts in a pre-revenue biotech.
- Fundamentals remain supported by a $519 million cash position and a pipeline advancing the Phase 3 PERFORMA trial in MASH.
- Get more detail on Altimmune's Price Targets, Earnings, and Forecast to complement this analysis.
- Explore Trending AI Robots to see how AI-driven strategies are tracking ALT and thousands of other tickers.
Altimmune (ALT) Company Overview and Market Position
Altimmune is a late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases. Its lead candidate, pemvidutide, is an investigational peptide designed as a balanced 1:1 glucagon/GLP-1 dual receptor agonist. The company is advancing pemvidutide across three indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).
The U.S. Food and Drug Administration has granted pemvidutide Fast Track designation for both MASH and AUD, as well as Breakthrough Therapy designation for MASH. Investors follow ALT as a differentiated player in the fast-growing metabolic and liver disease space, a category that has attracted intense attention given the commercial success of GLP-1 therapies. Because the company has no marketed products, it does not generate revenue and remains dependent on its cash reserves and financing to fund development.
Altimmune (ALT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ALT shares fell from approximately $2.96 to a latest close near $2.04, a decline of about 31%. The move was not a single-day gap but a steady, multi-week slide that accelerated in mid-October, with the stock reaching its recent low of the period.
The quarterly picture tells a similar but more nuanced story. ALT traded near $2.99 in late July, rallied to a multi-month high of about $3.42 in early September, and then reversed sharply to close near $2.04 in late October. On a quarter-over-quarter basis, the stock is down roughly 30%, meaning the September peak has been fully retraced and then some.
What Drove ALT Stock Price in the Last 30 Days
The last 30 days did not bring a major negative clinical readout or a single decisive catalyst for Altimmune. Instead, the decline appears to reflect a combination of profit-taking, a thinner slate of near-term catalysts, and broader pressure on small-cap biotechnology stocks.
After positive Phase 2 RECLAIM results in alcohol use disorder reported in late July and the announcement of the Phase 3 PERFORMA MASH trial initiation in August, the stock rallied into early September. With no new data events scheduled in the immediate weeks that followed, momentum faded and investors rotated out of a position that had already delivered a sizable run.
Additional factors likely weighed on sentiment. As a pre-revenue company, Altimmune is sensitive to interest-rate expectations and risk appetite, and small-cap biotech has faced sector-wide volatility. Financing overhang from earlier capital raises, including a $225 million public offering completed in April 2026, can also influence trading in the shares. In late October, the company announced new board appointments, part of a planned succession tied to its transition toward late-stage development.
What Drove ALT Stock Performance Over the Last Quarter
Altimmune's quarterly performance was defined by a sharp rise followed by an equally sharp reversal. In late July, the company reported positive topline results from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder, meeting its primary endpoint with a statistically significant reduction in heavy drinking days. In August, Altimmune initiated the global Phase 3 PERFORMA trial in MASH and completed patient enrollment in the Phase 2 RESTORE trial in alcohol-associated liver disease.
These milestones initially lifted the shares, but the absence of additional near-term readouts allowed sentiment to cool. Second-quarter results reported in August showed a narrower-than-expected net loss of $0.12 per share and a cash position of $519 million as of June 30, 2026, with management guiding a runway into 2029. While the balance sheet is strong, the long timelines to key data — ALD topline data in the second half of 2027 and MASH 52-week data anticipated in 2029 — mean the stock is now trading on a longer-horizon narrative rather than imminent catalysts.
Trending AI Robots
Tickeron operates a broad ecosystem of AI-powered trading bots, and its Trending AI Robots page showcases a curated selection of the most relevant, top-performing strategies. While Tickeron offers hundreds of bots that monitor thousands of tickers, only those demonstrating standout performance and relevance are highlighted in this section. The featured bots vary in trading strategy, timeframe, and performance metrics, giving investors a range of approaches to consider. For those interested in automated, data-driven ways to track stocks like Altimmune, the page offers a practical starting point to explore how AI systems approach the market.
ALT Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors will shape Altimmune's trajectory. Investors should monitor upcoming quarterly earnings reports, including the third-quarter 2026 update, for updates on cash position, R&D spending, and pipeline progress. Regulatory discussions with the FDA on a path forward in alcohol use disorder following the RECLAIM data represent a key near-term event, as does continued enrollment and execution in the Phase 3 PERFORMA MASH trial.
Longer-term, the Phase 2 RESTORE trial in alcohol-associated liver disease is expected to report topline data in the second half of 2027, while 52-week data from PERFORMA is anticipated in 2029. Competitive developments in the MASH landscape, including from Madrigal Pharmaceuticals (MDGL), and broader GLP-1 category dynamics will also influence sentiment. As a pre-revenue biotech, Altimmune's shares will likely remain sensitive to financing decisions, sector rotation, and shifts in risk appetite.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALT's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ALT turned positive on November 02, 2026. Looking at past instances where ALT's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALT's RSI Indicator exited the oversold zone, 37 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 70 cases where ALT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +7.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALT advanced for three days, in 204 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
ALT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALT as a result. In 77 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ALT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. ALT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.853) is normal, around the industry mean (3.498). P/E Ratio (-2.737) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (1678.863) settles around the average of (130.981) among similar stocks. ALT's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceuticals
Industry Biotechnology